(Q44254430)

1 December 2017

title

Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections (English)

1 reference

1 December 2017

main subject

Pseudomonas aeruginosa

0 references

1 reference

Baumann U

1

1 reference

1 December 2017

Mansouri E

series ordinal

2

1 reference

1 December 2017

von Specht BU

series ordinal

3

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

1 December 2017

1 reference

1 December 2017

volume

22

1 reference

1 December 2017

issue

7

1 reference

1 December 2017

page(s)

840-847

1 reference

Pseudomonas bacteremia in a community teaching hospital, 1980-1984

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Secular trends in nosocomial bloodstream infections in a 55-bed cardiothoracic intensive care unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Nosocomial infections in general surgery: surveillance report from a German university clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Burn wound infections: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Opportunistic infections in severely burned patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

High incidence of antibiotic resistance among bacteria in 4 intensive care units at a university hospital in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Intrinsic antibiotic resistance of Pseudomonas aeruginosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Immunization against Pseudomonas in infection after thermal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Controlled trials of a polyvalent pseudomonas vaccine in burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

A New Polyvalent Pseudomonas Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Naked DNA points way to vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Molecular and cellular basis of immune protection of mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Pathogenesis of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Association of Respiratory Tract Colonization with Adherence of Gram-Negative Bacilli to Epithelial Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Lung mucosal immunity: immunoglobulin-A revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Lymphocyte homing and homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Protein transport across the lung epithelial barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

7 January 2021

Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

7 January 2021

Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

7 January 2021

Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

7 January 2021

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.029

7 January 2021

10.1016/J.VACCINE.2003.11.029

Identifiers

DOI

1 reference

1 December 2017

1 reference